Potential use of IL-2/anti-IL-2 antibody immune complexes for the treatment of cancer and autoimmune disease
Initially discovered as a potent T cell proliferation factor, IL-2 was soon used for cancer immunotherapy, especially for metastatic melanoma and renal cell carcinoma; however, the severe side effects of IL-2 therapy, plus the negative role of IL-2 in maintaining of CD4+ CD25+ T regulatory cells (Tregs), has somewhat dampened enthusiasm for using IL-2 in immunotherapy. This opinion article discusses the possibility of combining IL-2 with certain anti-IL-2 antibodies for reducing the dose of IL-2 needed and preferentially stimulating effector T cells, but not Tregs, an approach that might provide an improved strategy for anticancer immunotherapy. Alternatively, complexes of IL-2 with other anti-IL-2 antibodies can selectively stimulate Tregs and could, therefore, be useful for treating autoimmune diseases.
|Authors||Boyman, O.;Surh, C. D.;Sprent, J. :|
|Publisher Name||EXPERT OPIN BIOL TH|
|Published Date||2006-01-01 00:00:00|
|OpenAccess Link||https://publications.gimr.garvan.org.au/download.php?2022_10543/06 Boyman EOBT.pdf|